

## CYP1B1 RABBIT PAB

货号: S210262

产品全名: CYP1B1 兔多抗

基因符号: CYP1B; GLC3A; CYP1B1; P4501B1

**UNIPROT ID:** Q16678 (Gene Accession - BC012049)

**背景:** This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The enzyme encoded by this gene localizes to the endoplasmic reticulum and metabolizes procarcinogens such as polycyclic aromatic hydrocarbons and 17beta-estradiol. Mutations in this gene have been associated with primary congenital glaucoma; therefore it is thought that the enzyme also metabolizes a signaling molecule involved in eye development, possibly a steroid.

**抗原:** Fusion protein of human CYP1B1

**经过测试的应用:** ELISA, IHC

**推荐稀释比:** IHC: 25-100; ELISA: 2000-5000

**种属反应性:** Rabbit

**克隆性:** Rabbit Polyclonal

**亚型:** Immunogen-specific rabbit IgG


**纯化:** Antigen affinity purification

**种属反应性:** Human, Mouse, Rat


**成分:** PBS (without Mg<sup>2+</sup> and Ca<sup>2+</sup>), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**研究领域:** Metabolism, Neuroscience, Cardiovascular


**储存和运输:** Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human thyroid cancer tissue using 210262(CYP1B1 Antibody) at a dilution of 1/20(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with the fusion protein and then with 210262(Anti-CYP1B1 Antibody) at dilution 1/20.



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using 210262(Anti-CYP1B1 Antibody) at a dilution of 1/20.



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with fusion protein and then with D120519(Anti-CYP1B1 Antibody) at dilution 1/20.



# Product Description

Pioneering GTPase and Oncogene Product Development since 2010

---